Federal Circuit Schedules Oral Argument for Enanta's Paxlovid Patent Appeal Against Pfizer

summarizeSummary

Enanta Pharmaceuticals announced that the Federal Circuit has scheduled oral arguments for May 11, 2026, in its patent infringement appeal against Pfizer concerning Paxlovid.

check_boxKey Events

• Oral Argument Scheduled

  The U.S. Court of Appeals for the Federal Circuit has scheduled oral arguments for May 11, 2026, in Enanta's appeal against Pfizer.

• Patent Infringement Lawsuit Update

  This update pertains to Enanta's ongoing appeal against Pfizer Inc. for infringement of U.S. Patent No. 11,358,953 related to Paxlovid.

auto_awesomeAnalysis

This 8-K provides a key procedural update in Enanta's patent infringement lawsuit against Pfizer regarding Paxlovid. The scheduling of oral arguments for May 11, 2026, indicates progress in a high-stakes legal battle that could result in substantial damages for Enanta if successful. Investors should monitor this date closely as the outcome of the appeal could significantly impact the company's financial outlook.